Recursion Pharmaceuticals (RXRX) EBIT Growth (3y) (2023 - 2026)

Recursion Pharmaceuticals (RXRX) EBIT Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 16.96%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 38.78%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -12.10%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 69.02%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Recursion Pharmaceuticals 1.59 Bn 933.22 Mn -6.02 Mn -22.52%

Historic Data

Download Data
DateValue
Mar 31, 2026 -22.52%
Dec 31, 2025 -21.11%
Sep 30, 2025 -40.14%
Jun 30, 2025 -38.60%
Mar 31, 2025 -50.64%
Dec 31, 2024 -41.43%
Sep 30, 2024 -28.46%
Jun 30, 2024 -34.93%
Mar 31, 2024 -46.75%
Dec 31, 2023 -56.97%
Sep 30, 2023 -64.23%
Jun 30, 2023 -64.92%
Mar 31, 2023 -56.17%